<DOC>
	<DOCNO>NCT01821027</DOCNO>
	<brief_summary>The purpose study determine multiple dos canagliflozin ( JNJ-28431754 ) affect pharmacokinetics ( ie , body affect drug ) pharmacodynamics ( ie , drug affect body ) single dose simvastatin .</brief_summary>
	<brief_title>A Study Assess Effects Canagliflozin ( JNJ-28431754 ) Pharmacokinetics , Pharmacodynamics , Safety Simvastatin Healthy Volunteers</brief_title>
	<detailed_description>This study open-label ( volunteer study staff know identity assign treatment ) , single-center , fixed-sequence study ( volunteer receive medication day order ) determine multiple dos canagliflozin ( drug currently investigate treatment type 2 diabetes mellitus ) affect pharmacokinetics pharmacodynamics single dose simvastatin ( drug use treat raise cholesterol ) . The study consist 3 phase : screening phase , open-label treatment phase , end-of-study ( follow-up ) phase . During open-label treatment phase , volunteer receive single 40 mg dose simvastatin Day 1 , follow 300 mg canagliflozin daily Days 2 6 . On Day 7 , volunteer receive simvastatin 40 mg canagliflozin 300 mg. Each volunteer participate study approximately 32 day</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Volunteers must body mass index ( BMI ) ( weight kg/height m2 ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Volunteers must nonsmoker History , current active illness , consider clinically significant Investigator , illness Investigator considers exclude patient study , could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Simvastatin ( ZOCOR )</keyword>
</DOC>